Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor.
about
Molecular Targeted Therapies of Aggressive Thyroid CancerAxitinib in Metastatic Renal Cell CarcinomaAxitinib Improves Radiotherapy in Murine Xenograft Lung Tumors.Impact of vegf on astrocytes: analysis of gap junctional intercellular communication, proliferation, and motility.Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.Fast rearrangement of the neuronal growth cone's actin cytoskeleton following VEGF stimulation.Monitoring sunitinib-induced vascular effects to optimize radiotherapy combined with soy isoflavones in murine xenograft tumorNew therapies for dedifferentiated papillary thyroid cancerInvolvement of corneal lymphangiogenesis in a mouse model of allergic eye diseaseSuccessful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.Morphological Plasticity of Emerging Purkinje Cells in Response to Exogenous VEGFGrowth factor restriction impedes progression of wound healing following cataract surgery: identification of VEGF as a putative therapeutic target.Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.Antiangiogenic activity and pharmacogenomics of medicinal plants from traditional korean medicine.Population pharmacokinetic analysis of axitinib in healthy volunteers.Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?Axitinib Induced Recurrent Pneumothorax following Near-Complete Response of Renal Cell Carcinoma Lung Metastasis: An Unexpected Complication.Clinical pharmacology of axitinib.Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma.Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.Emerging growth factor receptor antagonists for the treatment of advanced melanoma.Preclinical evaluation of mesenchymal stem cells overexpressing VEGF to treat critical limb ischemia.Vascular Endothelial Growth Factor, Irradiation, and Axitinib Have Diverse Effects on Motility and Proliferation of Glioblastoma Multiforme CellsCritical appraisal of axitinib in the treatment of advanced renal cell carcinoma.Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.Pharmacokinetics of single-agent axitinib across multiple solid tumor types.VEGF-induced growth cone enhancement is diminished by inhibiting tyrosine-residue 1214 of VEGFR-2.Influence of vascular endothelial growth factor and radiation on gap junctional intercellular communication in glioblastoma multiforme cell lines.Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma.Non-significant impact of proteinuria on renal function in Japanese patients with metastatic renal cell carcinoma treated with axitinib.
P2860
Q26774734-CA6BB0B7-44D9-4E1C-8392-85172ADEE829Q26998017-13E55323-74DC-4081-9545-B70A6AD981EBQ34092023-DB11CD68-11E2-45D0-8491-58E3157E86EAQ34202493-77DF5563-26F3-4A63-AEFF-68EEAF5B5E93Q34245458-65CF8938-A3CA-4547-B1D6-39FA4F426407Q34253081-FEB39E4A-9376-4A1E-B34B-2AAE6AFBEA1BQ34439734-D9EC4A81-BB92-4034-8C28-6449E315EAAAQ34754097-8F3554B3-600B-453A-B0A1-757C2CA09450Q35381593-60E4659E-8A3E-489A-A027-11DF0BA7760DQ35672575-708408C3-E1D0-4A20-9770-DD4C66A91A76Q35886777-3DEEB13C-87F5-4DD9-A106-D486365A82CAQ36279449-76346C38-2495-4C31-9E9A-2B0339E80989Q36796362-72024008-FBE0-4D32-A72B-187D17F6D10CQ36876472-C32EBA2B-AA2E-4F9B-993C-679280D1F464Q37077910-213E83D1-2C7E-4D7F-AE03-80EC9AD3D43BQ37635202-2CF6D919-72E4-43F1-BA01-0BF7AF37BF6BQ37799821-F6BE22EA-9ABB-44B2-BBEC-55E519D9E6BEQ38074659-FE5A7FD7-3F42-4DCA-9C1C-B7334B92AF84Q38107175-DB9CC940-D0AA-4169-900D-7BDA491CDDC7Q38163976-8E9D24D6-0072-4AF5-AC69-4601FC8FECBBQ38514440-DFC4DC05-8081-4C09-B855-9B8B0BC8622BQ38525073-BCDA5290-DD4D-4417-9274-C855A963C44EQ39340696-4FA1F0D0-1DF0-4C2B-BBD7-D30D7AA2C0EBQ40588724-7BFCF5A7-F209-462B-8C8E-DAFE96976388Q41525538-FDD48DEA-7FB6-4149-915A-CA4CE3DEE226Q41594914-51C22B27-2359-4A57-AFF9-E1B814F08A5FQ41872813-AE874C0B-6561-4A24-ACA5-598F480FB7A8Q44982199-52D002C2-DA4F-4B4B-ABD8-E32C7FF83773Q45280657-A94C4B64-26B4-4615-BD1A-FD2AA56EC209Q47104933-9E0C8BEE-FA26-434C-9986-789CCC318F95Q47692080-EDD09F30-0946-409D-816E-A98199878F47Q53001370-03DB7B27-DCE8-4ACD-89A6-4E302A4B28B7
P2860
Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Axitinib--a selective inhibito ...... growth factor (VEGF) receptor.
@en
Axitinib--a selective inhibitor of the vascular endothelial growth factor
@nl
type
label
Axitinib--a selective inhibito ...... growth factor (VEGF) receptor.
@en
Axitinib--a selective inhibitor of the vascular endothelial growth factor
@nl
prefLabel
Axitinib--a selective inhibito ...... growth factor (VEGF) receptor.
@en
Axitinib--a selective inhibitor of the vascular endothelial growth factor
@nl
P1433
P1476
Axitinib--a selective inhibito ...... growth factor (VEGF) receptor.
@en
P2093
Ronan J Kelly
P2888
P304
P356
10.1007/S11523-009-0126-9
P50
P577
2009-10-30T00:00:00Z